Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thoracic Neoplasms 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms × TNFSF10 protein, human × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡